# D-serine for the Schizophrenia Prodrome

> **NCT00826202** · PHASE2 · COMPLETED · sponsor: **Nathan Kline Institute for Psychiatric Research** · enrollment: 44 (actual)

## Conditions studied

- Schizophrenia Prodrome

## Interventions

- **DRUG:** D-serine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00826202
- **Lead sponsor:** Nathan Kline Institute for Psychiatric Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-08-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826202, "D-serine for the Schizophrenia Prodrome". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00826202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*